$10.22 (1935.86%)

Volume: 28.086k

Closed: Jun 05, 2023

Hollow Logo Score: 0.000
Acorda Therapeutics Stock
$10.22 (1935.86%)

Volume: 28.086k

Closed: Jun 05, 2023

Score Hollow Logo 0.000

Acorda Therapeutics Stock Company Profile

420 Saw Mill River Road

Ardsley NY 10502

914 347 4300


Acorda Therapeutics


Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Inbrija for the treatment of OFF periods in Parkinson's disease in Europe. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops ARCUS product for the treatment of acute migrain; rHIgM22, which has completed Phase I clinical trial for the treatment of MS; and Cimaglermin alfa for heart failure patients. The company has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. Acorda Therapeutics, Inc. was incorporated in 1995 and is headquartered in Ardsley, New York.

Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE